文 献 8）Ando-Matsuoka R, Yagi K, Takaoka M, Sakajiri Y, Shibata T, Sawada R, et al. Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells. Drug Dev Res 2023; 84(1): 75-83. 9）Jang YC, Huang HL, Leung, CY. Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis. BMC Cancer 2019; 19(1): 1199.10）Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: Estrogen pathway in colorectal cancer. Clin Cancer Res 2013; 19(21): 5842-8.11）Sawatsubashi S, Joko Y, Fukumoto S, Matsumoto T, Sugano SS. Development of versatile non-homologous end joining-based knock-in module for genome editing. Sci Rep 2018; 8(1): 593. 12）Ghezelayagh TS, Wu ES, Barber EL, Dao MD, Zsiros E, Urban RR, et al. Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. Eur J Gynaecol Oncol 2023; 44(1): 17-25. 13）Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004; 164(6): 1935-47.14）Limanówka P, Ochman B, Świętochowska E. Mechanisms behind the impact of PIWI proteins on cancer cells: Literature Review. Int J Mol Sci 2024; 25(22): 12217.60 1）Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28(11): 1779-802. 2）Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev 2020; 86: 102017. 3）Yagi K, Kajizono M, Maruo A, Shinmura W, Nitta Y, Yoshioka T, et al. Effective drug dosage rounding reduces healthcare expenses in the Japanese healthcare system. Drugs Ther Perspect 2025; 41: 160-67. 4）Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144(8): 1941-53. 5）Oliveira RF, Oliveira AI, Cruz AS, Ribeiro O, Afreixo V, Pimentel F. Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors. BMC Geriatr 2024; 24(1): 557. 6）Yagi K, Maruo A, Ishida S, Aizawa F, Ushio S, Sakaguchi S, et al. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study. Clin Exp Med 2023; 23(6): 2799-804. 7）Yagi K, Mitsui M, Zamami Y, Niimura T, Izawa-Ishizawa Y, Goda M, et al. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. Cancer Med 2021; 10(1): 164-72.
元のページ ../index.html#76